5 – 8 September 2007
Barcelona, Spain
Hotel Fira Palace

FIRST WORLD MEETING
OF INTERDISCIPLINARY
MELANOMA/SKIN CANCER CENTERS

Under the auspices of
European Association of Dermatologic Oncology

www.melanomacentersmeeting.com
The First World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, to take place in Barcelona Spain in September 2007, will be a unique opportunity for melanoma clinicians and researchers, who are part of multidisciplinary melanoma/skin cancer centers to interact, learn from one another, establish collaborations and set an agenda for the further evolution of multidisciplinary melanoma care and research.

The conference will feature Plenary Session speakers who are recognized experts in melanoma treatment and research. These Plenary Sessions will form the scientific backdrop for the meeting, and will highlight problem areas and opportunities in melanoma today. These Plenary Sessions will set the stage for a series of Breakout Sessions conducted by clinical and research experts, designed to focus attention and lead to new collaborative approaches in key areas where melanoma centers should be taking the lead.

The Breakout Sessions will address the following topics:

**Melanoma Education, Prevention and Training**

**Goals:** To facilitate international collaborations among multidisciplinary melanoma centers in melanoma patient education and early detection, and in melanoma prevention techniques and research. To develop strategies for further melanoma treatment and research by establishing melanoma training opportunities (eg, clinical or postdoctoral research fellowships) for clinicians and researchers in collaborative multidisciplinary melanoma centers.

**Melanoma Tumor Tissue Procurement and Collaborative Research**

**Goals:** To develop improved strategies for procuring fresh frozen and paraffin-embedded tissue from primary melanoma specimens that maximize both research opportunities and patient safety. To establish improved networks for collaboration among multidisciplinary melanoma centers worldwide, with a particular focus on increasing the level of collaboration between North American, Australian and European melanoma centers and between melanoma centers and existing cooperative oncology clinical research groups in North America and Europe.

**Melanoma Treatment and Clinical Trials**

**Goals:** To foster the more rapid dissemination of innovative melanoma diagnostic, imaging and treatment techniques among the world's melanoma centers. To establish networks for the rapid conduct of cutting edge clinical trials and biomarker correlative studies requiring large groups of patients with adequate follow up. To establish clinician researcher collaborations that allow the integration of correlative scientific studies into existing and future clinical trials conducted through the melanoma centers and the cooperative oncology clinical research groups.

After the initial specialty based session, subsequent sessions would be topic based and would include a mixture of specialists in each session, carrying forward the discussions started in the specialty breakout. Finally, “writing committees” selected during the last breakout session will be formed to summarize the discussions on each topic and provide a series of concrete suggestions and strategies, as well as ideas for developing funding sources when relevant.

The final “product” of these breakout sessions, and the Meeting as a whole, will be the written blueprint for the world’s multidisciplinary centers to move forward in a collaborative fashion to improve melanoma education, prevention, training, clinical care and research.

We look forward to seeing you in Barcelona in September!
Organizing Committee

Josep Malvehy. Barcelona, Spain
Claus Garbe. Tuebingen, Germany
Vernon Sondak. Tampa, Florida, USA
John Thompson. Sydney, Australia

Local Scientific Committee

Rafael Botella. Valencia, Spain
Cristina Carrera. Barcelona, Spain
Teresa Castel. Barcelona, Spain
Julian Conejo-Mir. Sevilla, Spain
Carlos Conill. Barcelona, Spain
Carlos Ferrandiz. Barcelona, Spain
Pedro Gascón. Barcelona, Spain
Carmen Herrero. Barcelona, Spain
Pablo Lázaro. Madrid, Spain
Cristina Mangas. Barcelona, Spain
Maribel Marmol. Barcelona, Spain
Rosa Martí. Lleida, Spain
Salvador Martín-Algarra. Pamplona, Spain
Susana Puig. Barcelona, Spain
Ramon Rull. Barcelona, Spain
Marcelo Sánchez. Barcelona, Spain
Sergi Vidal-Sicart. Barcelona, Spain
Antonio Vilalta. Barcelona, Spain
Ramon Vilella. Barcelona, Spain

Faculty

Sanjiv Agarwala. Bethlem, USA
Giuseppe Argenziano. Naples, Italy
Jürgen Becker. Wuerzburg, Germany
Antonio Buzaid. Sao Paulo, Brazil
Carlos Conill. Barcelona, Spain
Brigitte Dreno. Lyon, France
Alexander Eggertmont. Rotterdam, Netherlands
Richard Essner. Los Angeles, USA
Keith Flaherty. Philadelphia, USA
Claus Garbe. Tuebingen, Germany
Pedro Gascón. Barcelona, Spain
Jean-Jacques Grob. Marseille, France
Nelleke Gruis. Leiden, Netherlands
Axel Hauschild. Kiel, Germany
Peter Hersey. Newcastle, Australia
Ulrich Keilholz. Berlin, Germany
John Kirkwood. Pittsburgh, USA
Gilles Landmann. Sao Paulo, Brazil
Stanley Leong. San Francisco, USA
Paul Lorigan. Manchester, UK
Josep Malvehy. Barcelona, Spain
Salvador Martin-Algarra. Barcelona, Spain
Martin Mihm. Boston, USA
Hubert Pehamberger. Vienna, Austria
Giovanni Pellecani. Modena, Italy
Ketty Peris. L’Aquila, Italy
Victor Prieto. Houston, USA
Susana Puig. Barcelona, Spain
Antoni Ribas. San Francisco, USA
Jason Rivers. Vancouver, Canada
Caroline Robert. Paris, France
Merrick Ross. Houston, USA
Dirk Schadendorf. Mannheim, Germany
Stefania Seidenari. Modena, Italy
Vernon Sondak. Tampa, USA
Alexander Stratigos. Athens, Greece
John Thompson. Sydney, Australia
Hensin Tsao. Boston, USA
Selma Ugurel. Würzburg, Germany
Sergi Vidal-Sicart. Barcelona, Spain
Matthias Volkenandt. Munich, Germany
Iris Zalaudek. Graz, Austria
Wednesday, 5 September 2007

12.00 **PRESESSION. New drugs and new studies**
Chairpersons: Claus Garbe / Axel Hauschild

12.00 **CTLA-4/PD-1 pathway in regulating T-cell response and clinical trial data**
Jeffrey Weber [inquired]

12.25 **Heat shock protein 70 (STA4783).** Steve O’Day [inquired]

12.50 **Anti-integrin antibodies (CNT095).** Dirk Schadendorf

13.15 **RAF kinase inhibitors.** Axel Hauschild

13.40 **Sunitinib.** Martin Gore [inquired]

14.05 **Biomarkers.** Selma Ugurel

15.00 **SATELLITE SYMPOSIUM I**

17.00 **SATELLITE SYMPOSIUM II**

20.00 Welcome Reception, Fundació Miró

Thursday, 6 September 2007

08.15 **CASE PRESENTATIONS**
Chairpersons: Susana Puig / Iris Zalaudek / Giovanni Pellacani

09.00 **PLENARY SESSION 1. Primary and secondary prevention of melanoma**
Chairpersons: Jean-Jacques Grob / Jason Rivers
Key Issues. How to achieve exchanges in the behaviour of the public in order to decrease melanoma incidence? Is nevus screening worthwhile?

09.00 **The role of primary prevention in melanoma 2007.** Jason Rivers

09.15 **Risk factors for melanoma development.** Alexander Stratigos

09.30 **Low penetrance melanoma susceptibility genes.** Ketty Peris

09.45 **The GenoMEL Study of melanoma-prone families from three continents**
Nelleke Gruis

10.00 **Nevus screening – Who should be screened and how should it be done?**
Jean-Jacques Grob

10.15 **Statement of Chairpersons to Key Issues**

10.25 **Discussion**

11.00 Coffee - Break

11.30 **BASIC LECTURE A. Genetics and genomics in melanoma**
Hensin Tsao

12.15 Lunch / **POSTER VIEWING**

13.30 **BREAKOUT SESSIONS**

13.30 **Dermoscopy and new techniques.** Giuseppe Argenziano / Stefania Seidenari
Genetic testing and patient counselling in melanoma
Nelleke Gruis / Ketty Peris / Susana Puig

Establishment of scientific tissue banks. Victor Prieto / Dirk Schadendorf

15.00 **PLENARY SESSION 2. Melanoma diagnosis**
Chairpersons: Martin Mihm / Josep Malvehy
Key Issues. Should dermoscopy become a standard in melanoma diagnosis? Which molecular markers should be included in future work up of melanoma specimens?

15.00 **Dermoscopy in the diagnosis of initial melanomas.** Giuseppe Argenziano

15.15 **Challenges for dermoscopy and non invasive imaging in melanoma diagnosis**
Josep Malvehy

15.30 **Digital dermoscopy.** Stefania Seidenari
15.45 The use of tissue microarray as a tool to evaluate the importance of cell cycle proteins, integrins and metallo-proteinases in melanoma behaviour. Gilles Landmann
16.00 Molecular prognostic markers in melanoma. Martin Mihm
16.15 Statement of Chairpersons to Key Issues
16.25 Discussion
17.00 End of Session
17.00 Report from Breakout Sessions

Friday, 7 September 2007

08.15 CASE PRESENTATIONS
Chairpersons: Sergi Vidal-Sicart / Carles Conill

09.00 PLENARY SESSION 3. Melanoma surgery
Chairpersons: Alexander Eggermont / Vernon Sondak
Key Issues. What are the present standards in melanoma surgery? Should metastasectomy have a greater role in stage IV melanoma?
09.00 Surgical management of melanoma: Standards, new insights and the biology behind Alexander Eggermont
09.15 Shall we perform sentinel node biopsy if benefit for overall survival is lacking? Stanley Leong
09.30 Reversal of immune suppression in sentinel lymph nodes. Richard Essner
09.45 Role of surgical metastasectomy in stage IV melanoma. Vernon Sondak
10.00 Future directions of melanoma staging. Merrick Ross
10.15 Statement of Chairpersons to Key Issues
10.25 Discussion
11.00 Coffee - Break
11.30 BASIC LECTURE B. Essentials of guideline development for melanoma
John Thompson
12.15 Lunch / POSTER VIEWING

13.30 BREAKOUT SESSIONS
Is SLNB appropriate in 2007? If so, in which patients? Merrick Ross / Vernon Sondak
Organization of melanoma centers/Study centers. Claus Garbe / John Thompson
Investigator initiated trials. Ulrich Keilholz / Sanjiv Agarwala

15.00 PLENARY SESSION 4. Targeted and individualized approaches to future melanoma therapy
Chairpersons: Keith Flaherty / Hubert Pehamberger
Key Issues. Which are the most promising targets for future melanoma treatment? How can melanoma therapy be individualized?
15.00 Targeting signal transduction pathways in melanoma. Keith Flaherty
15.15 Molecular targets – Others than signal transduction proteins. Paul Lorigan
15.30 Targeting tumor apoptosis. Hubert Pehamberger
15.45 Sorafenib. Sanjiv Agarwala
16.00 How to individualize systemic therapies in melanoma. Jürgen Becker
16.15 Statement of Chairpersons to Key Issues
16.25 Discussion
17.00 End of Session
17.00 Report from Breakout Sessions
Saturday, 8 September 2007

08.15 CASE PRESENTATIONS  
Chairpersons: Pedro Gascón / Salvador Martín-Algarra

09.00 PLENARY SESSION 5. Immunotherapy  
Chairpersons: Peter Hersey / Antoni Ribas  
Key Issues. Does vaccination have a role in future melanoma treatment?  
How can different immunotherapeutic strategies be combined?

09.00 Melanoma vaccination with cell line derived antigens. Current results and perspectives  
Peter Hersey

09.15 Dendritic cell vaccination. Dirk Schadendorf

09.30 CTLA4 antibodies. Antoni Ribas

09.45 T-cell mediated melanoma treatment – How can it be developed? Brigitte Dreno

10.00 Cutaneous adverse events of new anti-cancer drugs. Caroline Robert

10.15 Statement of Chairpersons to Key Issues

10.25 Discussion

11.00 Coffee - Break

11.30 BASIC LECTURE C. Communication with the cancer patient  
Matthias Volkenandt

12.15 Lunch / POSTER VIEWING

13.30 BREAKOUT SESSIONS

  Documentation and quality control. John Thompson / Claus Garbe
  Future directions of adjuvant melanoma treatment  
  Alexander Eggermont / John Kirkwood
  Recommendations for first and second line treatment in stage IV melanoma  
  Keith Flaherty / Axel Hauschild

15.00 PLENARY SESSION 6. Systemic treatment of melanoma  
Chairpersons: John Kirkwood / Axel Hauschild  
Key Issues. Can general recommendation be given for adjuvant melanoma treatment?  
What is the recommendation for first and second line systemic melanoma treatment in stage IV disease?

15.00 What is the role of interferon-alpha in future melanoma treatment? – The US perspective. John Kirkwood

15.15 What is the role of interferon-alpha in future melanoma treatment? – The European perspective. Claus Garbe

15.30 Treatment of melanoma with cytotoxic drugs in the decade of targeted therapies  
Ulrich Keilholz

15.45 Has chemoimmuno-therapy a role in melanoma treatment? Antonio Buzaid

16.00 Overview on recent and ongoing clinical trials. Axel Hauschild

16.15 Statement of Chairpersons to Key Issues

16.25 Discussion

17.00 End of Session

17.00 Report from Breakout Sessions
Congress Venue
FIRA PALACE HOTEL****
Av. Rius i Taulet, 1-3
08004 Barcelona

Dates September 5-8, 2007

Language and translation. The official language of the meeting will be English. No simultaneous translation will be provided, except in the plenary sessions.

Exhibition
A Commercial Exhibition will take place at the Congress Venue, in close proximity to the main meeting rooms. If you are interested in participating as exhibitor, please ask for more information to General Secretariat.

Abstract submission - Deadline June 15th, 2007
If you wish to submit an abstract, please follow the instructions given at the Congress website www.melanomacentersmeeting.com

Registration and Hotel Accommodation
Please visit the Congress website for those purposes www.melanomacentersmeeting.com

Fees (VAT included)
<table>
<thead>
<tr>
<th></th>
<th>Early registration: June 15th</th>
<th>From June 16th</th>
<th>On site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegates</td>
<td>€ 300</td>
<td>€ 500</td>
<td>€ 600</td>
</tr>
<tr>
<td>Residents and Eastern Countries</td>
<td>€ 200</td>
<td>€ 350</td>
<td>€ 400</td>
</tr>
<tr>
<td>Accompanying person*</td>
<td>€ 100</td>
<td>€ 100</td>
<td>€ 150</td>
</tr>
</tbody>
</table>

* Welcome Reception only
After August 26th all registrations will have to be ON SITE, at the Meeting Venue
Registration fee includes: entrance to the scientific sessions and to the Exhibition Area, documentation, coffee-breaks and admission to the Welcome Reception.

Welcome Reception - Wednesday, 5 September
The Cocktail will be held in the Fundació Miró, the most important collection of Joan Miró’s work. The Foundation enjoys a prime location overlooking the city from the magnificent vantage point of Montjuïc Park and also is meeting point where culture and leisure come together in a rich and varied series of spaces. Private visit to the Museum.

Cancellation policy
From January 1st until July 30th a 50% refund. Between August 1st and August 31st a 25%. After September 1st, no refund.
The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force majeure, or should the nonappearance of speakers or other reasons need programme changes. With registration, the participant accepts this proviso.

Insurance
The Organizer do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

Passport and visa
Identity card is required to entry in Spain for people from EEC countries. For people from non EEC countries a valid passport is required. A visa may be required for some countries. For information about visa and passports contact the Spanish embassy in your country at least 3 months prior to your departure to Spain.
Main Sponsors

Platinum
Schering-Plough

Gold
Bayer HealthCare
Bayer Schering Pharma

Silver
Genta